Group Mailing 2000-06-01

Priority Lists

Disease Committee	Last Changed
Breast Cancer	3/6/26
Cancer Care Delivery	8/4/25
comboMATCH	10/16/25
Early Therapeutics & Rare Cancers	11/7/25
Gastrointestinal Cancer	12/30/25
Genitourinary Cancer	1/19/26
Head and Neck Cancer	10/16/25
iMATCH	12/3/25
Immunomolecular Therapeutics	12/3/25
Leukemia	12/30/25
Lung Cancer	9/8/25
LungMAP	4/24/25
Lymphoma	10/23/25
Melanoma	11/7/25
Myeloma	10/23/25
myeloMATCH	12/30/25
Other	2/1/14
Palliative Care	10/24/25
Prevention, Screening, and Surveillance	1/1/25
Sarcoma	9/15/07
SWOG CTP	10/16/25
Symptom Management and Survivorship	10/24/25

S9712Phase II

Phase II Trial of Concurrent Carboplatin/VP-16 and Radiation Followed by Paclitaxel (Taxol®) For Poor-Risk Stage III Non-Small Cell Lung Cancer

Study Coordinator(s)	Derick H.M. Lau, M.D.,Ph.D., David R. Gandara, M.D., Laurie E. Gaspar, M.D.
Participants	Members, NCORP
Closure Date	2000-06-01

S0008Phase III Intergroup

Phase III Trial of High Dose Interferon Alpha-2b versus Cisplatin, Vinblastine, DTIC Plus IL-2 and Interferon in Patients with High Risk Melanoma

Study Coordinator(s)	Lawrence E. Flaherty, M.D., John A. Thompson, M.D., Ralph J. Tuthill, M.D., John Vetto, M.D., Vernon K. Sondak, M.D., Jeffrey A. Sosman, M.D.
Participants	Members, NCORP, Medical Oncologists, Surgeons, Pathologists, ECOG, COG, US INSTITUTIONS ONLY